CDKN1B and hepatocellular carcinoma: Furthermore, reduced CDKN1B expression often predicts poor clinical outcomes in HCC (Huang et al., 2011; Matsuda et al., 2013), and CDKN1B silencing increases the viability of HCC cells (Xu et al., 2019).